Piramal Pharma Limited Reports Strong Financial Results for Q2 and Half Year of FY27

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) has made headlines with the announcement of their financial results for the Second Quarter (Q2) and Half Year (H1) ending September 30, 2026. The company showcased robust growth across its key business units, with significant improvements in both revenue and profitability that reflect its strategic direction and operational effectiveness.

Financial Highlights

The recently released consolidated financial results reveal a remarkable 28% year-over-year (YoY) growth in revenue for Q2 FY27, totaling ₹2,617 crores, up from ₹2,044 crores in Q2 FY26. For the first half of the fiscal year, the revenue surged by 23% to ₹4,887 crores, compared to ₹3,977 crores in H1 FY26. This impressive performance is attributed primarily to the successful execution of the company’s overarching business strategies and market demand.

Particularly notable is the Contract Development and Manufacturing Organization (CDMO) segment, which reported a 36% YoY rise in revenue for Q2, achieving ₹1,424 crores, while the Complex Hospital Generics (CHG) segment grew by 32% YoY, indicating broad-based growth across all sectors.

EBITDA and Profitability Improvements

Piramal Pharma also reported substantial enhancements in profitability, with an EBITDA of ₹385 crores for Q2 FY27, marking a 72% increase YoY. The EBITDA margin expanded to 14.7%, a considerable improvement from 11.0% in Q2 FY26. The first half also reflected similar trends, with EBITDA for H1 FY27 reaching ₹669 crores, further underscoring the company’s disciplined execution and efficiency in operations.

Nandini Piramal, Chairperson of Piramal Pharma Limited, noted, “Our results demonstrate the strength of demand across our businesses and improved operational leverage. The performance was driven by our CDMO division, which grew significantly due to strong order inflows and the efficient execution of ongoing projects. Our overall operations indicate a sustained momentum moving forward.”

Business Segment Highlights

1. CDMO Performance:
- The CDMO segment showcased remarkable growth, supported by strong demand both within India and globally. The addition of 22 new customers and an increase in their Phase III pipeline to 28 molecules affirmed their expanding footprint in the market.
- Revenues from innovation-related activities increased 24%, while on-patent commercial manufacturing revenues surged 39%, reflecting a successful product pipeline and customer engagement tactics.

2. Complex Hospital Generics:
- Maintaining leadership in critical areas, the company achieved a 48% market share in the US Sevoflurane market while building traction in ex-US territories.
- The integration of Kenalog® has been a substantial growth driver for the CHG business, showcasing the effectiveness of their operational strategy.

3. Consumer Healthcare Expansion:
- With the Power Brands segment growing 21% YoY and strong e-commerce performance, which rose by 32%, this division is poised for continuous growth. Their recent launches, focused on premium products, further align with market trends favoring high-quality consumer goods.

Future Outlook

The strong performance in H1 FY27 led Piramal Pharma to upgrade its revenue growth outlook for the fiscal year. They now anticipate revenue growth of 19% to 20%, accompanied by improved profitability as the company continues to capitalize on its robust order book and operational efficiencies.

In summary, Piramal Pharma Limited's Q2 and H1 FY27 results not only demonstrate substantial revenue and profit growth but also indicate strong potential as the company leverages its comprehensive strategies to meet market demands. With continuous investment in innovation and operational efficiencies, Piramal Pharma is well-positioned to uphold its leadership in the pharmaceutical sector.